335
Participants
Start Date
May 8, 2019
Primary Completion Date
June 12, 2020
Study Completion Date
September 28, 2020
TAK-385
TAK-385 40 mg tablets + Leuprorelin acetate placebo injection
Leuprorelin acetate
TAK-385 placebo tablets + Leuprorelin acetate 1.88 mg / 3.75 mg injection
Chubu Rosai Hospital, Aichi
Meitetsu Hospital, Aichi
Aiiku Ladies Clinic, Chiba
Chiba Aoba Municipal Hospital, Chiba
Tokyo Bay Urayasu Ichikawa Medical Center, Chiba
Tsujinaka Hospital Kashiwanoha, Chiba
Fujito Clinic, Hiroshima
Hashimoto Clinic, Hokkaido
Tokeidai Memorial Hospital, Hokkaido
Yoshio Obstetrics Gynecology Hospital, Hokkaido
Shinsuma Hospital, Hyōgo
Kagawa Prefectural Central Hospital, Kagawa
Takamatsu Red Cross Hospital, Kagawa
Fujisawa City Hospital, Kanagawa
Rinkan Clinic, Kanagawa
Second Kawasaki Saiwai Clinic, Kanagawa
Tawada Ladies Clinic, Kanagawa
Japanese Red Cross Kumamoto Hospital, Kumamoto
Kurashiki Medical Clinic, Okayama
Chayamachi Ladies Clinic, Osaka
Hayakawa Clinic, Osaka
Minami-Morimachi Ladies Clinic, Osaka
Nomura Clinic Nanba, Osaka
Rikako Ladies Clinic, Osaka
Tanabe Ladies Clinic, Osaka
Yoshimura Ladies Clinic, Osaka
Dantsuka Clinic, Saitama
Kashiwazaki Ladies Clinic, Saitama
Maruyama Memorial General Hospital, Saitama
Kusatsu General Hospital, Shiga
Akasaka-Mitsuke Miyazaki Clinic, Tokyo
Ginza Yoshida Hospital, Tokyo
Hamada Hospital, Tokyo
Ikebukuro Metroporitan Clinic, Tokyo
NS Clinic, Tokyo
Sei Women's Clinic, Tokyo
Seijo Kinoshita Hospital, Tokyo
Shimamura Memorial Hospital, Tokyo
Toranomon Women's Clinic, Tokyo
Yokokura Clinic, Tokyo
Yukawa Women's Clinic, Tokyo
Lead Sponsor
ASKA Pharmaceutical Co., Ltd.
INDUSTRY